https://orcid.org/0000-0002-3784-4229
References
- Montano N, Conforti G, Di Bonaventura R, et al. Advances in diagnosis and treatment of trigeminal neuralgia. Ther Clin Risk Manag. 2015Feb;11:289‐299. DOI:10.2147/TCRM.S37592
- Cruccu G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013‐1028.
- Rudà R, Houillier C, Maschio M, et al. Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: results from a prospective, noninterventional study in European clinical practice (VIBES). Epilepsia. 2020;61(4):647‐656.
- Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007;13(1):21‐42.
- Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019;26(6):831‐849.
- Gómez-Argüelles JM, Bermejo PE, Lara M, et al. Efectividad de la lacosamida en el tratamiento del dolor neuropatico refractario: estudio observacional abierto [Effectiveness of lacosamide in the treatment of refractory neuropathic pain: an open observational trial]. Rev Neurol. 2014;59(7):289‐293.
- Sanchez-Larsen A, Sopelana D, Diaz-Maroto I, et al. Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia. Eur J Pain. 2018;22(6):1080‐1087.
- Zhu LN, Chen D, Tan G, et al. The tolerability and safety profile of eslicarbazepine acetate in neurological disorders. J Neurol Sci. 2020;413:116772.
- Zutshi D, Yarraguntla K, Mahulikar A, et al. Racial variations in lacosamide serum concentrations in adult patients with epilepsy. J Neurol Sci. 2020;412:116742.
- Biton V, Fountain N, Rosenow F, et al. Safety and tolerability of lacosamide: a summary of adverse events in epilepsy clinical trials. Ann Neurol. 2008;64(Suppl 12):S21.
- Schultz L, Mahmoud SH. Is therapeutic drug monitoring of lacosamide needed in patients with seizures and epilepsy? Eur J Drug Metab Pharmacokinet. 2020;45(3):315‐349.
- Biton V, Gil-Nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav. 2015;52((Pt A):119‐127.
- Rogawski MA, Tofighy A, White HS, et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015;110:189‐205.
- Stöhr T, Kupferberg HJ, Stables JP, et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 2007;74(2–3):147‐154.
- Tayama T, Mori T, Goji A, et al. Improvement of epilepsy with lacosamide in a patient with ring chromosome 20 syndrome. Brain Dev. 2020;42(6):473‐476.
- Numoto S, Kurahashi H, Iwayama H, et al. A trial of lacosamide for benign convulsions with gastroenteritis [published online ahead of print, 2020 Apr 9]. Brain Dev. 2020;S0387-7604(20):30115–30117.
- Allard J, Henley W, Mclean B, et al. Lacosamide in the general population and in people with intellectual disability: similar responses? Seizure. 2020 Feb 19;76:161–166. DOI:10.1016/j.seizure.2020.02.013. Epub ahead of print.
- Errington AC, Stöhr T, Heers C, et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73(1):157‐169.
- Moutal A, Chew LA, Yang X, et al. (S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. Pain. 2016;157(7):1448‐1463.
- Rocamora R, Ley M, Molins A, et al. Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: A prospective multicenter study. Epilepsy Behav. 2018;79:87‐92.
- Cuomo I, Kotzalidis GD, De Filippi S, et al. Clinical stabilisation with lacosamide of mood disorder comorbid with PTSD and fronto-temporal epilepsy. Acta Biomed. 2017;88(2):185‐189. DOI:10.23750/abm.v88i2.5232. Published 2017 Aug 23.
- Argyriou AA, Kalofonou F, Litsardopoulos P, et al. Real world, open label experience with Lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2020 Apr 10. DOI:10.1111/jns.12374. [ Epub ahead of print. PMID: 32277545].
- Schoedel KA, Andreas JO, Doty P, et al. Randomized, double-blind, placebo- and active comparator-controlled crossover study evaluating the abuse potential of the antiepileptic drug lacosamide in healthy recreational drug users. J Clin Psychopharmacol. 2017;37(6):675‐683.